$2.39
3.02% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US6294441000
Symbol
NRXP

NRX Pharmaceuticals Inc Stock price

$2.39
-0.82 25.55% 1M
-0.55 18.71% 6M
+0.19 8.64% YTD
+0.34 16.59% 1Y
-5.61 70.11% 3Y
-104.21 97.76% 5Y
-93.61 97.51% 10Y
-93.61 97.51% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.07 3.02%
ISIN
US6294441000
Symbol
NRXP
Industry

Key metrics

Basic
Market capitalization
$45.3m
Enterprise Value
$48.1m
Net debt
$2.9m
Cash
$5.6m
Shares outstanding
17.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 1.4
EV/Sales
- | 1.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-636.1%
Return on Equity
108.2%
ROCE
69.4%
ROIC
83.6%
Debt/Equity
-0.3
Financials (TTM | estimate)
Revenue
$0.0 | $33.2m
EBITDA
$-17.5m | -
EBIT
$-17.5m | $-3.3m
Net Income
$-24.1m | $-2.2m
Free Cash Flow
$-10.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
28.5% | -
EBIT
28.5% | 83.1%
Net Income
6.0% | 91.3%
Free Cash Flow
45.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -6.6%
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-0.6
Short interest
4.5%
Employees
-
Rev per Employee
-
Show more

Is NRX Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

NRX Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a NRX Pharmaceuticals Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a NRX Pharmaceuticals Inc forecast:

Buy
90%
Hold
10%

Financial data from NRX Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
4% 4%
-
- Research and Development Expense 5.26 5.26
54% 54%
-
-17 -17
28% 28%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -17 -17
28% 28%
-
Net Profit -24 -24
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about NRX Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NRX Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
one day ago
WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpha...
Neutral
PRNewsWire
one day ago
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data...
Neutral
PRNewsWire
5 days ago
Florida's Agency for Health Care Administration (AHCA) approval is a critical regulatory step toward closing the Dura Medical acquisition Dura Medical, together with previously-announced acquisitions of Neurospa TMS, and Cohen and Associates, to provide coverage along the West Coast of Florida Dura delivers a full range of precision psychiatry services for severe depression, PTSD and related CN...
More NRX Pharmaceuticals Inc News

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Head office United States
CEO Jonathan Javitt
Founded 2017
Website www.nrxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today